| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
https://azure.microsoft.com/en-us/blog/driving-roi-with-azure-ai-foundry-and-uipath-intelligent-agents-in-real-world-healthcare...
UiPath (NYSE:PATH), a global leader in agentic automation, today announced that it has achieved ISO/IEC 42001:2023 certificatio...
UBS analyst Jeff Hickey upgrades UiPath (NYSE:PATH) from Sell to Neutral and raises the price target from $10 to $17.